← Back to All US Stocks

CDT Equity Inc. (CDTTW) Stock Fundamental Analysis & AI Rating 2026

CDTTW Nasdaq Pharmaceutical Preparations DE CIK: 0001896212
Updated This Month • Analysis: Mar 22, 2026 • SEC Data: 2025-09-30
Combined AI Rating
STRONG SELL
90% Confidence
STRONG AGREEMENT
STRONG SELL
92% Conf
STRONG SELL
89% Conf

📊 CDTTW Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-11.3M
Current Ratio: 1.66x
Debt/Equity: 0.05x
EPS: $-74.92
AI Rating: STRONG SELL with 92% confidence
CDT Equity Inc. (CDTTW) receives a STRONG SELL rating with 90% confidence from our AI fundamental analysis based on SEC 10-K filings., and return on equity (ROE) of -418.4% Below is our complete CDTTW stock analysis for 2026.

Is CDT Equity Inc. (CDTTW) a Good Investment?

Claude

CDT Equity is a pre-revenue pharmaceutical company with severe cash burn and negative profitability across all metrics. The company is burning approximately $11.3M in free cash flow annually with only $3.8M in cash reserves, creating a critical runway issue without additional financing.

ChatGPT

CDT Equity Inc. shows very weak fundamentals: it appears pre-revenue or effectively non-commercial, with persistent operating and net losses, deeply negative returns on assets and equity, and materially negative free cash flow. While leverage is low and liquidity is still above 1x, the balance sheet is small relative to the current cash burn, making future dilution or external financing a significant risk unless the company can materially improve operating performance.

Why Buy CDT Equity Inc. Stock? CDTTW Key Strengths

Claude
  • + Modest long-term debt of only $200K limiting leverage risk
  • + Current ratio of 1.66x indicates adequate short-term liquidity
  • + Pharmaceutical sector positioning if clinical/regulatory milestones achieved
ChatGPT
  • + Low financial leverage, with debt/equity of just 0.05x
  • + Current and quick ratios of 1.66x indicate near-term obligations are still covered
  • + Positive equity balance and $3.84M cash provide limited short-term operating flexibility

CDTTW Stock Risks: CDT Equity Inc. Investment Risks

Claude
  • ! No revenue generation with complete dependence on cash reserves for operations
  • ! Negative free cash flow of -$11.3M annually with only ~10 months of cash runway remaining
  • ! Extreme negative returns (ROE -418.4%, ROA -209.3%) and operating margin of N/A indicating losses on minimal asset base
  • ! Operating losses of -$15.6M and net losses of -$17.9M with deteriorating EPS
  • ! Pre-clinical/early-stage status with no clear path to revenue or profitability
ChatGPT
  • ! No meaningful revenue base, making profitability and growth quality difficult to support
  • ! Heavy annual losses and negative free cash flow imply a short cash runway relative to burn
  • ! Extremely negative ROE and ROA indicate weak capital efficiency and high dependence on future funding

Key Metrics to Watch

Claude
  • * Monthly cash burn rate and runway to profitability or capital raise
  • * Clinical trial progress and regulatory milestones
  • * Insider buying/selling activity for signal of management confidence
  • * Operating loss trends and ability to extend cash runway
ChatGPT
  • * Quarterly operating cash burn versus cash balance
  • * Any emergence of sustainable revenue or material narrowing of operating losses

CDT Equity Inc. (CDTTW) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
$-17.9M
EPS (Diluted)
$-74.92
Free Cash Flow
$-11.3M
Total Assets
$8.6M
Cash Position
$3.8M

💡 AI Analyst Insight

CDT Equity Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

CDTTW Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -418.4%
ROA -209.3%
FCF Margin N/A

CDTTW vs Healthcare Sector: How CDT Equity Inc. Compares

How CDT Equity Inc. compares to Healthcare sector averages

Net Margin
CDTTW 0.0%
vs
Sector Avg 12.0%
CDTTW Sector
ROE
CDTTW -418.4%
vs
Sector Avg 15.0%
CDTTW Sector
Current Ratio
CDTTW 1.7x
vs
Sector Avg 2.0x
CDTTW Sector
Debt/Equity
CDTTW 0.0x
vs
Sector Avg 0.6x
CDTTW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is CDT Equity Inc. Stock Overvalued? CDTTW Valuation Analysis 2026

Based on fundamental analysis, CDT Equity Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-418.4%
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.05x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

CDT Equity Inc. Balance Sheet: CDTTW Debt, Cash & Liquidity

Current Ratio
1.66x
Quick Ratio
1.66x
Debt/Equity
0.05x
Debt/Assets
50.0%
Interest Coverage
-78.01x
Long-term Debt
$200.0K

CDTTW Revenue & Earnings Growth: 5-Year Financial Trend

CDTTW 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: CDT Equity Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-61,598.62 indicates the company is currently unprofitable.

CDTTW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

CDT Equity Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$10.9M
Cash generated from operations
Stock Buybacks
$114.1M
Shares repurchased (TTM)
Capital Expenditures
$398.0K
Investment in assets
Dividends
None
No dividend program

CDTTW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for CDT Equity Inc. (CIK: 0001896212)

📋 Recent SEC Filings

Date Form Document Action
Apr 15, 2026 10-K form10-k.htm View →
Mar 30, 2026 4 xslF345X06/ownership.xml View →
Mar 25, 2026 8-K form8-k.htm View →
Mar 18, 2026 8-K form8-k.htm View →
Mar 9, 2026 8-K form8-k.htm View →

Frequently Asked Questions about CDTTW

What is the AI rating for CDTTW?

CDT Equity Inc. (CDTTW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are CDTTW's key strengths?

Claude: Modest long-term debt of only $200K limiting leverage risk. Current ratio of 1.66x indicates adequate short-term liquidity. ChatGPT: Low financial leverage, with debt/equity of just 0.05x. Current and quick ratios of 1.66x indicate near-term obligations are still covered.

What are the risks of investing in CDTTW?

Claude: No revenue generation with complete dependence on cash reserves for operations. Negative free cash flow of -$11.3M annually with only ~10 months of cash runway remaining. ChatGPT: No meaningful revenue base, making profitability and growth quality difficult to support. Heavy annual losses and negative free cash flow imply a short cash runway relative to burn.

What is CDTTW's revenue and growth?

CDT Equity Inc. reported revenue of N/A.

Does CDTTW pay dividends?

CDT Equity Inc. does not currently pay dividends.

Where can I find CDTTW SEC filings?

Official SEC filings for CDT Equity Inc. (CIK: 0001896212) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CDTTW's EPS?

CDT Equity Inc. has a diluted EPS of $-74.92.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is CDTTW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, CDT Equity Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is CDTTW stock overvalued or undervalued?

Valuation metrics for CDTTW: ROE of -418.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy CDTTW stock in 2026?

Our dual AI analysis gives CDT Equity Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is CDTTW's free cash flow?

CDT Equity Inc.'s operating cash flow is $-10.9M, with capital expenditures of $398.0K.

How does CDTTW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -418.4% (avg: 15%), current ratio 1.66 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-09-30 | Powered by Claude AI